Incidence of Thromboembolic Events During Neoadjuvant Therapy for (borderline) Resectable Pancreatic Adenocarcinoma: A Side-study of the PREOPANC-2 Trial | AMiner
Incidence of Thromboembolic Events During Neoadjuvant Therapy for (borderline) Resectable Pancreatic Adenocarcinoma: A Side-study of the PREOPANC-2 Trial
R.A.L. Willems,E.N. Dekker,A.E. van Diepen,N. Michiels,M.G. Besselink,M.Y.V. Homs,G. van Tienhoven,J.W. Wilmink,C.H.J. van Eijck,B. Groot Koerkamp,J. de Vos-Geelen
原文链接
分享
引用
